Physician profile
Eugene M Fine
NPI 1699841718
$2,244.88
in general payments reported to CMS, 2019-2025
18 companies · $80.12 in 2025
The $80.12 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $335 · 2021: $280 · 2022: $463 · 2023: $264 · 2024: $258 · 2025: $80.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.98 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $618.12 | 2019-2025 | |
| Janssen Biotech, INC. | $487.14 | 2019-2023 | Erleada |
| Abbvie INC. | $169.34 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.88 | 2019-2023 | |
| Urovant Sciences INC | $143.80 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $123.48 | 2019-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $112.16 | 2019-2020 | |
| Blue Earth Diagnostics | $90.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $67.73 | 2020-2023 | Keytruda, Lynparza |
| Zyla Life Sciences, INC. | $65.52 | 2020 | |
| Coloplast Corp | $54.25 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $23.46 | 2023 | Gemtesa |
| Astellas Pharma US INC | $23.17 | 2020 | |
| Endo Pharmaceuticals INC. | $23.05 | 2019 | |
| Clarus Therapeutics INC. | $21.50 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $20.81 | 2023 | |
| Allergan, INC. | $20.00 | 2019 | |
| Progenics Pharmaceuticals, INC. | $16.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.